Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management
- 1 May 2018
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Asco Educational Book
- Vol. 38 (38), 13-19
- https://doi.org/10.1200/edbk_100013
Abstract
Gastrointestinal toxicities are among the leading causes of immune-related adverse effects of checkpoint blockade. These adverse events can be severe enough to require interruption or withdrawal of immune checkpoint blockade therapy. Patients with immune-related adverse effects require early recognition with an evaluation to rule out alternative etiologies and effective management to minimize complications. This article reviews the gastrointestinal and hepatic toxicities of the antibodies that target immune checkpoints CTLA-4 and PD-1/PD-L1 and provides an approach to their diagnosis and management.Keywords
This publication has 34 references indexed in Scilit:
- Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary CancersFrontiers in Oncology, 2017
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJournal of Clinical Oncology, 2017
- Management of toxicities of immune checkpoint inhibitorsCancer Treatment Reviews, 2016
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals Of Oncology, 2015
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisBMC Medicine, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumabCancer, 2013
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010